UG United-Guardian Inc.

UNITED-GUARDIAN REPORTS FY-2019 FINANCIAL RESULTS

UNITED-GUARDIAN REPORTS FY-2019 FINANCIAL RESULTS

HAUPPAUGE, N.Y., March 19, 2020 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported today that sales and earnings for FY-2019 were up slightly from 2018, with sales increasing from $13,445,565 to $13,599,084, and net income increasing from $4,352,331 ($0.95 per share) to $4,761,711 ($1.04 per share), an increase in earnings of 9.4%.

“Although we were one of many companies that were negatively impacted by the trade war between the U.S. and China in 2019, our sales into China were still considerable, and we expect China to remain an important market for us, especially as the impact of the coronavirus diminishes,” said Ken Globus, President of United-Guardian. “Our sales in China, as well as in Korea, were also impacted by increased competition from lower-priced Asian competitors, but we are optimistic that our appointment of a new marketing partner in Korea will enable us to recover some of the business we lost there.”

“Offsetting the lower sales of our cosmetic ingredients was a 33% increase in sales of our medical lubricants, which have become an increasingly important revenue source for us,” continued Mr. Globus. “We also experienced a 19% increase in sales of Renacidin® Irrigation, our most important pharmaceutical product, the sales of which have been increasing since we began our internet marketing campaign. We are continuing to work closely with all our marketing partners to develop new and innovative ingredients for the cosmetic market, especially “natural” ingredients, and plan to have several new products in the hands of our marketing partners this year. We are hopeful that we will be able to increase the sales of not only our cosmetic ingredients, but our medical and pharmaceutical products as well, and that despite the global economic impact of the coronavirus, 2020 can be another profitable year for us.”

United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products. 

Contact:

Robert S. Rubinger

(631) 273-0900

NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause the company’s actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

 
FINANCIAL RESULTS FOR THE YEARS ENDED

DECEMBER 31, 2019 AND DECEMBER 31, 2018
 
STATEMENTS OF INCOME
    
  Years ended December 31,  
  2019  2018 
       
Net sales$13,599,084 $13,445,565 
       
Costs and expenses:      
Cost of sales 5,657,353  5,343,459 
Operating expenses 2,148,375  2,122,746 
Research and development 397,391  399,517 
Total costs and expenses 8,203,119  7,865,722 
Income from operations   5,395,965    5,579,843 
Other income (expense):      
Investment income 203,329  231,986 
Net gain (loss) on marketable securities 431,076  (333,138)
Loss on trade-in of equipment ---  (12,837)
Total other income (expense) 634,405  (113,989)
       
Income before provision for income taxes 6,030,370  5,465,854 
       
Provision for income taxes 1,268,659  1,113,523 
Net income$4,761,711 $4,352,331 
       
Earnings per common share (basic and diluted)$1.04 $0.95 
       
Weighted average shares (basic and diluted) 4,594,319  4,594,319 
       



 
BALANCE SHEET DATA

(condensed)
   
  December 31,
  2019  2018 
       
Current assets$11,567,281 $11,687,100 
Property, plant, and equipment (net of depreciation) 780,707  827,925 
Other assets (net) 14,824  29,647 
Total assets 12,362,812  12,544,672 
       



Current liabilities 1,343,059  1,366,151 
Deferred income taxes (net) 386,855  253,583 
Total Liabilities 1,729,914  1,619,734 
       
Stockholders’ equity 10,632,898  10,924,938 
Total liabilities and stockholders’ equity$12,362,812 $12,544,672 
       
EN
19/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on United-Guardian Inc.

 PRESS RELEASE

United-Guardian Reports First Quarter Results

United-Guardian Reports First Quarter Results HAUPPAUGE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the first quarter of 2025. First quarter sales decreased from $3,254,944 in 2024 to $2,481,127 in 2025, with net income decreasing from $925,442 ($0.20 per share) to $560,895 ($0.12 per share). Donna Vigilante, President of United-Guardian, stated, “We are experiencing a slow start to 2025 compared to the beginning of 2024. While we saw positive performance from our medical lubricant and pharmaceutical businesses, ...

 PRESS RELEASE

United-Guardian Reports 2024 Financial Results

United-Guardian Reports 2024 Financial Results HAUPPAUGE, N.Y., March 21, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2024 increased compared to FY 2023. Net sales for the year increased by 12% from $10,885,154 in 2023 to $12,181,971 in 2024, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,581,370 ($0.56 per share) in 2023. Donna Vigilante, President of United-Guardian, stated, “We are pleased to announce that net sales and net income increased from 2023 to 2024. Sales of cosmetics ingredients a...

 PRESS RELEASE

United-Guardian Declares Cash Dividend

United-Guardian Declares Cash Dividend HAUPPAUGE, N.Y., Jan. 30, 2025 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today that the company's Board of Directors, at its meeting on January 27, 2025, declared a cash dividend of $0.35 per share, to be paid on February 18, 2025, to all stockholders of record as of the close of business on February 10, 2025. This will be the 30th consecutive year that the company has paid a dividend. Donna Vigilante, President of United-Guardian, stated, “I am pleased to report that the company’s Board of Directors has decided to distribute a...

 PRESS RELEASE

United-Guardian Reports Increased Third Quarter Earnings

United-Guardian Reports Increased Third Quarter Earnings HAUPPAUGE, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2024. Sales for the nine-month period ended September 30th increased from $8,278,141 in 2023 to $9,705,262 in 2024 and net income increased from $1,843,931 ($0.40 per share) to $2,747,151 ($0.60 per share) for the same period. The third quarter remained steady with sales of $3,057,518 in 2023 and $3,060,113 in 2024, while net income increased from $626,756 ($0.1...

 PRESS RELEASE

United-Guardian Reports Increased Second Quarter Sales & Earnings

United-Guardian Reports Increased Second Quarter Sales & Earnings HAUPPAUGE, N.Y., Aug. 09, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2024. Sales for the six-month period ended June 30th increased from $5,220,623 in 2023 to $6,645,149 in 2024 and net income increased from $1,217,175 ($0.26 per share) to $1,881,667 ($0.41 per share) for the same period. Second quarter sales increased from $2,650,299 in 2023 to $3,390,205 in 2024, with net income increasing from $461,094 ($0.10 per share) to $956...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch